For a better user experience please update your browser or use Chrome or Firefox browser.
Utilities
Publication detail
HomeExpert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA
Publication metadata
The multicomponent meningococcal B (4CMenB) vaccine Bexsero for the prevention of serogroup B invasive meningococcal disease (SgB IMD) has been available in the European Union/European Economic Area (EU/EEA) since 2013. Meningococcal serogroup B (SgB) is the most common cause of IMD in all age groups at the aggregated EU/EEA level. SgB IMD predominantly affects infants and young children and is the leading cause of mortality and morbidity related to IMD in children under five years of age. The aim of this document is to provide an ECDC expert opinion on the introduction of the 4CMenB vaccine in the Member States of the EU/EEA. This expert opinion document is intended to support national decision-making by summarising the considerations and concerns of some EU/EEA countries when they discussed whether to introduce the 4CMenB vaccine into their national immunisation programmes. It also summarises the reasons behind national recommendations for the 4CMenB vaccine, points out data gaps, and presents options on how to introduce the vaccine.
- Published:
- Corporate author(s): European Centre for Disease Prevention and Control (EU body or agency)
- Themes: Public health , Health policy
- Subject: disease prevention , infant mortality , infectious disease , public health , report , vaccination , vaccine
|
PDF
|
|||
| ISSN | ISBN 978-92-9498-163-9 | DOI 10.2900/18933 | Catalogue number TQ-05-17-226-EN-N |
- Released on EU publications website:
Document viewer
Note:
The publication cannot be displayed in the document viewer. Open web version
You may access it from: Download and languages